CTIS2023-508703-21-00
Recruiting
Phase 1
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers - MK-9999-02A
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 139
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Has one of the following cancers: •Unresectable or metastatic colorectal cancer •Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) •Advanced and/or unresectable biliary tract cancer (BTC), 2\.Has received one previous treatment for the cancer (colorectal cancer, PDAC); has received one or two previous treatments for BTC, 3\.Has recovered from any side effects due to previous cancer treatment
Exclusion Criteria
- •1\.History of severe eye disease, 2\.Received prior treatment with a trophoblast cell surface antigen 2 (TROP2\)\-targeted antibody\-drug conjugate (ADC)., 3\.Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL)CTIS2023-505840-20-00Astrazeneca AB153
Recruiting
Phase 1
AGN-193408 SR in the treatment of open-angle glaucoma or ocular hypertensioOpen-angle glaucomaOcular hypertensionJPRN-jRCT2031220053Yamazaki Hayato84
Active, not recruiting
Phase 1
Study conducted to learn more about the safety and effects of CTX001 (the Study Therapy”) in patients with Severe Sickle Cell DiseaseSickle Cell DiseaseMedDRA version: 20.0Level: PTClassification code 10043391Term: Thalassaemia betaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2018-001320-19-ITVERTEX PHARMACEUTICALS INCORPORATED45
Active, not recruiting
Phase 1
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat Severe Sickle Cell DiseaseSevere Sickle Cell Disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040641Term: Sickle cell anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2018-001320-19-GBVertex Pharmaceuticals Incorporated45
Active, not recruiting
Phase 1
An early study to test IMGN901 with carboplatin and etoposide for treating adult patients with certain types of cancer including small cell lung cancerPhase 2: small cell lung cancer (extensive-stage disease)MedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10041058 Term: Small cell carcinoma of the lung System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-022950-17-GBImmunoGen, Inc181